How Does the Breast DCIS Score Test Compare to Other Tests?

The Breast DCIS Score test vs. traditional assessment methods

With a DCIS patient, the key to choosing the right treatment plan is assessing the patient’s risk for local recurrence (DCIS or invasive carcinoma). Traditionally, this assessment is based only on clinical and pathologic factors or nomograms (that rely on population-based estimates of average risk).

the first and only clinically-validated, commercially available genomic test for patients with DCIS

The Breast DCIS Score test provides an individualized assessment of risk, so you can better personalize the treatment plan for each patient’s unique situation. Performed on a tumor sample after a biopsy or surgery, the test looks at the unique biology of a patient’s tumor. The Breast DCIS Score report includes information not available from any other test, such as1-3:

  • An individualized prediction of the 10-year risk of any local recurrence (DCIS or invasive carcinoma) or an invasive local recurrence.
  • An established baseline for consideration of absolute benefit from radiation therapy (XRT).
  • Quantitative ER and PR single gene expression values.

In addition, the DCIS Score result provides an easy-to-understand score (a number from 0-100) that estimates the patient’s risk for local recurrence. The report makes talking to patients about their test results easier and more efficient.

Genomic testing vs. genetic testing

Genetic tests help people understand their risk for getting cancer. Genomic tests help people who have been diagnosed with cancer plan their care. The Breast DCIS Score test examines 12 cancer-related genes in a patient’s tumor. The activity of these genes influences the behavior of the tumor, including how likely it is to grow and spread. The Breast DCIS Score test looks at these genes to help you and your patient make decisions about appropriate care.

Breast DCIS Score test vs. Breast Recurrence Score test 

The Breast DCIS Score is specifically for patients with ductal carcinoma in situ (DCIS) treated by local excision. The Oncotype DX Breast Recurrence Score test is a similar test for patients with early-stage and ER-positive invasive breast cancer.


1. Solin et al. J Natl Cancer Inst. 2013.
2. Rakovitch et al. Breast Cancer Res Treat. 2015.
3. Rakovitch et al. J Natl Cancer Inst. 2017.

a. DOI: 10.1007/s10549-015-3464-6

Making cancer care smarter.®